Adjuvant Chemotherapy Combined With Gonadotropin-releasing Hormone Analog For Premenopausal Breast Cancer:A Meta-Analysis About The Benefit Of Survival

Objective To systematically evaluate the efficacy of gonadotropin-releasing hormone analog(GnRHa)combined with adjuvant chemotherapy in premenopausal women with breast cancer.Methods The search was performed to identify prospective random control trials published in the domestic and overseas during 1996 to 2018 comparing adjuvant chemotherapy with or without GnRHa in premenopausal women with breast cancer.Jadad grading standard was used to appraise the quality of the included studies.STATA 12.0 was used to conduct the Meta-analysis.Results With 5 eligible Phase III clinical randomized controlled trials(RCTs)identified,this analysis demonstrated that premenopausal patients with breast cancer didn,t derive benefit in disease-free survival(DFS)[HR=0.880,95%CI(0.769,1.006),P=0.06],but derived benefit in overall survival(OS)[HR=0.808,95%CI(0.660,0.988),P=0.038]from the addition of GnRHa to adjuvant chemotherapy.Conclusion GnRHa combined with adjuvant chemotherapy in premenopausal patients with breast cancer derived benefit in overall survival,which needs more mature data and analysis in the future.